Supporting multiple modalities and manufacturing workflows
Pall Corporation has extended its bioprocessing technology portfolio with the launch of three new Allegro Connect Systems.
In conjunction with Pall’s Allegro single-use portfolio, it said these systems are designed to deliver enhanced process and risk control, through the full automation of unit operations that combine to support the production of a wide range of therapeutic drugs and vaccines.
The Allegro Connect Systems portfolio now includes systems to support Depth Filtration, Virus Filtration and Bulk Fill of drug substance, and join the Buffer Management System to simplify the creation of manufacturing workflows.
Pall said the Allegro Connect Systems integrate previously manual operations, such as filter integrity testing and single-use system leak testing, reducing the need for operator intervention. With intuitive hardware, software and consumable designs, the process is simplified from installation through to batch reporting, with streamlined access to critical process data for faster, more secure batch release, added the developer.
Ed Hoare, vice president and general manager for biotech at Pall Corporation, said: “In an increasingly dynamic bioprocessing environment, the challenge of supporting a growing variety of modalities and manufacturing workflows can easily lead to proliferation of system designs and a complex array of solutions. These can slow the specification cycle and often lead to rigid system designs that struggle to keep pace with changing process demands. Our new Allegro Connect System design combines our decades of bioprocessing knowledge with direct insights from process owners and developers to simplify those choices and deliver greater process flexibility through optimized configurability.”
